BACKGROUND: The 5-year graft survival rate of donor kidneys transplanted in the Eurotransplant Senior Program (ESP) is only 47 per cent. Normothermic machine perfusion (NMP) may be a new preservation technique that improves graft outcome. This pilot study aimed to assess safety and feasibility of this technique within the ESP. METHODS: Recipients were eligible for inclusion if they received a donor kidney within the ESP. Donor kidneys underwent 2 h of oxygenated NMP with a red cell-based solution at 37°C, additional to standard-of-care preservation (non-oxygenated hypothermic machine perfusion). The primary outcome was the safety and feasibility of NMP. As a secondary outcome, graft outcome was investigated and compared with that in a historical group of patients in the ESP and the contralateral kidneys. RESULTS: Eleven patients were included in the NMP group; the function of eight kidneys could be compared with that of the contralateral kidney. Fifty-three patients in the ESP, transplanted consecutively between 2016 and 2018, were included as controls. No adverse events were noted, especially no arterial thrombosis or primary non-function of the transplants. After 120 min of oxygenated NMP, median flow increased from 117 (i.q.r. 80-126) to 215 (170-276) ml/min (P = 0.001). The incidence of immediate function was 64 per cent in the NMP group and 40 per cent in historical controls (P = 0.144). A significant difference in graft outcome was not observed. DISCUSSION: This pilot study showed NMP to be safe and feasible in kidneys transplanted in the ESP. A well powered study is warranted to confirm these results and investigate the potential advantages of NMP on graft outcome.
BACKGROUND: The 5-year graft survival rate of donor kidneys transplanted in the Eurotransplant Senior Program (ESP) is only 47 per cent. Normothermic machine perfusion (NMP) may be a new preservation technique that improves graft outcome. This pilot study aimed to assess safety and feasibility of this technique within the ESP. METHODS: Recipients were eligible for inclusion if they received a donor kidney within the ESP. Donor kidneys underwent 2 h of oxygenated NMP with a red cell-based solution at 37°C, additional to standard-of-care preservation (non-oxygenated hypothermic machine perfusion). The primary outcome was the safety and feasibility of NMP. As a secondary outcome, graft outcome was investigated and compared with that in a historical group of patients in the ESP and the contralateral kidneys. RESULTS: Eleven patients were included in the NMP group; the function of eight kidneys could be compared with that of the contralateral kidney. Fifty-three patients in the ESP, transplanted consecutively between 2016 and 2018, were included as controls. No adverse events were noted, especially no arterial thrombosis or primary non-function of the transplants. After 120 min of oxygenated NMP, median flow increased from 117 (i.q.r. 80-126) to 215 (170-276) ml/min (P = 0.001). The incidence of immediate function was 64 per cent in the NMP group and 40 per cent in historical controls (P = 0.144). A significant difference in graft outcome was not observed. DISCUSSION: This pilot study showed NMP to be safe and feasible in kidneys transplanted in the ESP. A well powered study is warranted to confirm these results and investigate the potential advantages of NMP on graft outcome.
Authors: Michèle J de Kok; Dagmara McGuinness; Paul G Shiels; Dorottya K de Vries; Joanne B Tutein Nolthenius; Leonie G Wijermars; Ton J Rabelink; Lars Verschuren; Karen S Stevenson; David B Kingsmore; Martin McBride; Rutger J Ploeg; Esther Bastiaannet; Alexander F Schaapherder; Jan H Lindeman Journal: Ann Surg Date: 2019-11 Impact factor: 12.969
Authors: Friedrich K Port; Jennifer L Bragg-Gresham; Robert A Metzger; Dawn M Dykstra; Brenda W Gillespie; Eric W Young; Francis L Delmonico; James J Wynn; Robert M Merion; Robert A Wolfe; Philip J Held Journal: Transplantation Date: 2002-11-15 Impact factor: 4.939
Authors: Anja Gallinat; Cyril Moers; Jürgen Treckmann; Jacqueline M Smits; Henry G D Leuvenink; Rolf Lefering; Ernest van Heurn; Günter R Kirste; Jean-Paul Squifflet; Axel Rahmel; Jacques Pirenne; Rutger J Ploeg; Andreas Paul Journal: Nephrol Dial Transplant Date: 2012-07-26 Impact factor: 5.992
Authors: Cyril Moers; Jacqueline M Smits; Mark-Hugo J Maathuis; Jürgen Treckmann; Frank van Gelder; Bogdan P Napieralski; Margitta van Kasterop-Kutz; Jaap J Homan van der Heide; Jean-Paul Squifflet; Ernest van Heurn; Günter R Kirste; Axel Rahmel; Henri G D Leuvenink; Andreas Paul; Jacques Pirenne; Rutger J Ploeg Journal: N Engl J Med Date: 2009-01-01 Impact factor: 91.245
Authors: Alix P M Matton; Laura C Burlage; Rianne van Rijn; Yvonne de Vries; Shanice A Karangwa; Maarten W Nijsten; Annette S H Gouw; Janneke Wiersema-Buist; Jelle Adelmeijer; Andrie C Westerkamp; Ton Lisman; Robert J Porte Journal: Liver Transpl Date: 2018-04 Impact factor: 5.799
Authors: Annemarie Weissenbacher; John P Stone; Maria Letizia Lo Faro; James P Hunter; Rutger J Ploeg; Constantin C Coussios; James E Fildes; Peter J Friend Journal: Front Med (Lausanne) Date: 2022-01-10
Authors: Elsaline Rijkse; Sarah Bouari; Hendrikus J A N Kimenai; Jeroen de Jonge; Ron W F de Bruin; Julia S Slagter; Martijn W F van den Hoogen; Jan N M IJzermans; Martin J Hoogduijn; Robert C Minnee Journal: Int J Surg Protoc Date: 2021-10-06